Elesclomol
Small moleculeexperimental
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2003 (NCT00088114)
Timeline
Indications
Mechanism of action
- Adrenodoxin, mitochondrialINHIBITOR
inhibitor - FDX1
Chemistry & pharmacology
Loading structure…
SMILES
CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1- Mol. weight
- 400.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1972860 ↗
Also known as
- elesclomol
- elesclomol
- elesclomol
- elesclomol
- elesclomol
- sta4783
- sta 4783
- sta 4783
- sta 4783
- sta-4783
- sta-4783
- sta-4783
- sta-4783
- sta-4783
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01280786 | Phase 1 | Jan 1, 2011 | Synta Pharmaceuticals Corp. |
| NCT00888615 | Phase 2 | Dec 1, 2010 | Gynecologic Oncology Group, National Cancer Institute (NCI), NRG Oncology |
| NCT00827203 | Phase 1 | Jan 1, 2009 | Synta Pharmaceuticals Corp. |
| NCT00808418 | Phase 1 | Nov 1, 2008 | Synta Pharmaceuticals Corp. |
| NCT00522834 | Phase 3 | Aug 1, 2007 | Synta Pharmaceuticals Corp. |
| NCT00087997 | Phase 2 | Jul 1, 2004 | Synta Pharmaceuticals Corp. |
| NCT00084214 | Phase 1/Phase 2 (Phase 2) | May 1, 2004 | Synta Pharmaceuticals Corp. |
| NCT00088088 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2004 | Synta Pharmaceuticals Corp. |
| NCT00088114 | Phase 1 | Jan 1, 2003 | Synta Pharmaceuticals Corp. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Synta Pharmaceuticals Corp. | For profit | 8 | 8 | 3 | 2003 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2010 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1